share_log

石藥集團：自願公告 - 根據股份獎勵計劃在市場上購買股份

CSPC PHARMA: VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES ON-MARKET PURSUANT TO THE SHARE AWARD SCHEME

Hong Kong Stock Exchange ·  Apr 26 05:33
Summary by Moomoo AI
石藥集團有限公司（「石藥集團」）於2024年4月26日根據其2018年8月20日採納的限制性股份獎勵計劃，在市場上購買了合共4,790,000股股份，佔已發行股份總數約0.040%，平均每股代價約為6.554港元，總代價約31,393,400港元。該批股份將由計劃受託人以信託方式持有，並為獲選參與者的利益而保留。此外，石藥集團董事會將繼續檢討及決定未來是否繼續從市場購買股份以及授予獲選參與者的股份數目。董事會成員包括執行董事及獨立非執行董事，由主席蔡東晨先生領導。
石藥集團有限公司（「石藥集團」）於2024年4月26日根據其2018年8月20日採納的限制性股份獎勵計劃，在市場上購買了合共4,790,000股股份，佔已發行股份總數約0.040%，平均每股代價約為6.554港元，總代價約31,393,400港元。該批股份將由計劃受託人以信託方式持有，並為獲選參與者的利益而保留。此外，石藥集團董事會將繼續檢討及決定未來是否繼續從市場購買股份以及授予獲選參與者的股份數目。董事會成員包括執行董事及獨立非執行董事，由主席蔡東晨先生領導。
Petropharmacy Group Limited (the “Petropharmacy Group”) purchased on the market on 26 April 2024 under its Restrictive Share Award Scheme adopted on 20 August 2018, a total of 4,790,000 shares representing approximately 0.040% of the total issued shares, at an average price per share of approximately HK$6.554 at a total cost of approximately HK$31,393,400 meta. The lot of shares will be held in trust by the plan trustee and retained for the benefit of the selected participants. In addition, the Board of Directors of Petropharmaceuticals Group will continue to review and decide whether to continue purchasing shares from the market and the number of shares to be granted to selected participants in the future. The members of the Board of Directors include Executive Directors and Independent Non-Executive Directors, led by Mr. Cai Tung Chen, Chairman.
Petropharmacy Group Limited (the “Petropharmacy Group”) purchased on the market on 26 April 2024 under its Restrictive Share Award Scheme adopted on 20 August 2018, a total of 4,790,000 shares representing approximately 0.040% of the total issued shares, at an average price per share of approximately HK$6.554 at a total cost of approximately HK$31,393,400 meta. The lot of shares will be held in trust by the plan trustee and retained for the benefit of the selected participants. In addition, the Board of Directors of Petropharmaceuticals Group will continue to review and decide whether to continue purchasing shares from the market and the number of shares to be granted to selected participants in the future. The members of the Board of Directors include Executive Directors and Independent Non-Executive Directors, led by Mr. Cai Tung Chen, Chairman.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more